¼¼°èÀÇ ¹«Ç¥Áö ¾î·¹ÀÌ ½Ã½ºÅÛ ½ÃÀå
Label-free Array Systems
»óǰÄÚµå : 1655521
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 193 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,301,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,905,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ¹«Ç¥Áö ¾î·¹ÀÌ ½Ã½ºÅÛ ½ÃÀåÀº 2030³â±îÁö 24¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 18¾ï ´Þ·¯¿¡ À̸¥ °ÍÀ¸·Î ÃßÁ¤µÇ´Â ¹«Ç¥Áö ¾î·¹ÀÌ ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 24¾ï ´Þ·¯¿¡ À̸£°í, ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGR 5.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠǥ¸é ÇÁ¶óÁî¸ó °ø¸í(SPR) ±â¼úÀº CAGR 5.8%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 18¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »ýüÃþ °£¼·¹ý(Bio-layer Interferometry : BLI) ±â¼ú ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ CAGR 5.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 8,430¸¸ ´Þ·¯, Áß±¹Àº CAGR 5.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹«Ç¥Áö ¾î·¹ÀÌ ½Ã½ºÅÛ ½ÃÀåÀº 2024³â¿¡ 4¾ï 8,430¸¸ ´Þ·¯¿¡ À̸¥ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGR 5.3%·Î ¼ºÀåÇÏ¿© 2030³â±îÁö 3¾ï 8,280¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 5.3%¿Í 4.7%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹«Ç¥Áö ¾î·¹ÀÌ ½Ã½ºÅÛ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ¼ºÀå ÃËÁø¿äÀÎ Á¤¸®

¹«Ç¥Áö ¾î·¹ÀÌ ½Ã½ºÅÛÀº »ýÀÇÇÐ ¿¬±¸¸¦ ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

¹«Ç¥Áö ¾î·¹ÀÌ ½Ã½ºÅÛÀº Çü±¤ Ç¥Áö³ª ¹æ»ç¼º Ç¥Áö ¾øÀ̵µ »ýü ºÐÀÚÀÇ »óÈ£ÀÛ¿ëÀ» ½Ç½Ã°£À¸·Î ºñħ½ÀÀûÀ¸·Î ºÐ¼®ÇÒ ¼ö ÀÖ¾î »ýÀÇÇÐ ¿¬±¸¿¡ ¸Å¿ì À¯¿ëÇÑ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀ» ÅëÇØ °úÇÐÀÚµéÀº ¼¼Æ÷ ¹ÝÀÀ, ´Ü¹éÁú »óÈ£ÀÛ¿ë, Áúº´ °æ·Î¸¦ º¸´Ù ÀÚ¿¬½º·´°Ô ¿¬±¸ÇÒ ¼ö ÀÖÀ¸¸ç, ½Å¾à °³¹ß, Áø´Ü, ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ¹«Ç¥Áö ±â¼úÀº ºÐÀÚ°£ »óÈ£ÀÛ¿ë¿¡ ´ëÇÑ ÅëÂû·ÂÀ» Á¦°øÇÔÀ¸·Î½á º¸´Ù ºü¸£°í Á¤È®ÇÑ µ¥ÀÌÅÍ ¼öÁýÀ» Áö¿øÇϰí, ¿¬±¸ ¹æ¹ýÀÇ È¿À²¼ºÀ» ³ôÀ̸ç, »õ·Î¿î Ä¡·á¹ý °³¹ßÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½Å¾à°³¹ß¿¡ ÀÖ¾î ¹«¶óº§ ±â¼úÀÇ ÀåÁ¡Àº ¹«¾ùÀΰ¡?

½Å¾à °³¹ß¿¡¼­ Á¦¾à ¿¬±¸ÀÚµéÀº ¶óº§¿¡ ÀÇÇÑ ºÐÀÚ °Åµ¿ º¯È­ÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­Çϸ鼭 ÀáÀçÀûÀÎ ¾à¹° »óÈ£ ÀÛ¿ëÀ» Á÷Á¢ Á¶»çÇÒ ¼ö ÀÖ½À´Ï´Ù. °áÇÕ Ä£È­µµ, µ¿·ÂÇÐÀû ÇÁ·ÎÆÄÀÏ, ¼¼Æ÷ ¹ÝÀÀÀ» ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ¾î ¾à¹° ½ºÅ©¸®´× °úÁ¤ÀÇ Á¤È®¼ºÀ» Çâ»ó½Ã۰í, À¯¸ÁÇÑ È­ÇÕ¹°À» Á¶±â¿¡ ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¶óº§ÀÌ ¾ø´Â ½Ã½ºÅÛÀº ¶óº§ ±â¹Ý ºÐ¼®°ú °ü·ÃµÈ ºñ¿ë°ú ½Ã°£À» ÁÙ¿© º¸´Ù È¿À²ÀûÀÌ°í ºñ¿ë È¿À²ÀûÀÎ ½Å¾à °³¹ß ÆÄÀÌÇÁ¶óÀÎÀ» Áö¿øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¤È®¼º°ú È¿À²¼ºÀ¸·Î ÀÎÇØ ¹«Ç¥Áö ¾î·¹ÀÌ ½Ã½ºÅÛÀº Çö´ë Á¦¾à ¿¬±¸¿¡¼­ ¼±È£µÇ´Â Á¢±Ù¹ýÀÌ µÇ¾ú½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ¶óº§ ÇÁ¸® ½Ã½ºÅÛÀ» ¾î¶»°Ô °³¼±Çϰí Àִ°¡?

Ãֱ٠ǥ¸é ÇöóÁî¸ó °ø¸í(SPR), »ýüÃþ °£¼·¹ý(BLI) µîÀÇ °ËÃâ¹ýÀÇ ¹ßÀüÀº ¹«Ç¥Áö ¾î·¹ÀÌ ½Ã½ºÅÛÀÇ ¹Î°¨µµ¿Í ¹ü¿ë¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ´õ ÀÛÀº ±Ô¸ð¿¡¼­ ´õ Á¤¹ÐÇÑ ºÐ¼®À» °¡´ÉÇÏ°Ô Çϰí, Àú³óµµÀÇ »ýüºÐÀÚ °ËÃâ°ú º¹ÀâÇÑ ½Ã·áÀÇ ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÚµ¿È­¿Í µ¥ÀÌÅÍ ºÐ¼®°úÀÇ ÅëÇÕÀ» ÅëÇØ 󸮷®À» ´õ¿í Çâ»ó½ÃÄÑ ´ë±Ô¸ð ¿¬±¸¸¦ À§ÇÑ ÇÏÀ̽º·çDz ½ºÅ©¸®´×À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °ËÃâ ¹× ºÐ¼®ÀÇ Çâ»óÀ¸·Î ¶óº§ ÇÁ¸® ½Ã½ºÅÛÀÇ ¿ëµµ°¡ È®´ëµÇ°í ¿¬±¸ ¹× ÀÓ»ó ÇöÀå¿¡¼­ÀÇ °¡Ä¡°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

¹«Ç¥Áö ¾î·¹ÀÌ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù.

¹«¶óº§ ¾î·¹ÀÌ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº Á¤È®Çϰí 󸮷®ÀÌ ³ôÀº ½Å¾à °³¹ß Åø¿¡ ´ëÇÑ ¼ö¿ä, °ËÃâ ±â¼úÀÇ ¹ßÀü, È¿À²ÀûÀÎ »ýü ºÐÀÚ ºÐ¼®ÀÇ Çʿ伺 µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç¿Í »ý¸í°øÇÐ ±â¾÷µéÀÌ ½Å¾à ½ºÅ©¸®´×À» À§ÇÑ º¸´Ù Á¤¹ÐÇÑ ÅøÀ» ¿ä±¸Çϰí ÀÖ´Â °¡¿îµ¥, ¹«¶óº§ ½Ã½ºÅÛÀº ¼Óµµ¿Í Á¤È®¼º¿¡¼­ ¿ìÀ§¸¦ Á¡Çϰí ÀÖ½À´Ï´Ù. ½Ã½ºÅÛÀÇ ¹Î°¨µµ¸¦ ³ôÀÌ°í ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ±â¼ú °³¹ßµµ ½ÃÀåÀÇ °¡´É¼ºÀ» ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, È¿°úÀûÀÎ Áø´Ü µµ±¸¿Í ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö µµ±¸ÀÇ Çʿ伺ÀÌ »ý¸í°úÇÐ ¿¬±¸¿¡¼­ Áß¿äÇÑ Àåºñ·Î ÀÚ¸®¸Å±èÇϸ鼭 ¹«Ç¥Áö ¾î·¹ÀÌ ½Ã½ºÅÛ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ÀÀ¿ë ºÐ¾ß(½Å¾à °³¹ß, Ç×ü Ư¼ºÈ­ ¹× °³¹ß, ´Ü¹éÁú ÀÎÅÍÆäÀ̽º ºÐ¼®, ´Ü¹éÁú º¹ÇÕü ¹× ij½ºÄÉÀÌµå ºÐ¼®); ÃÖÁ¾ ¿ëµµ(R&D ¿¬±¸¼Ò, ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO), ³ó¾÷ ¿¬±¸ ±â°ü, ±âŸ ÃÖÁ¾ ¿ëµµ); ±â¼ú(Ç¥¸é ÇöóÁî¸ó °ø¸í(SPR), »ý¹°Ãþ °£¼· ÃøÁ¤(BLI), ¼¼Æ÷ À¯Àüü ºÐ±¤¹ý(CDS), ¼®¿µ Å©¸®½ºÅ» ¸¶ÀÌÅ©·Î¹ë·±½º)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(43°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Label-free Array Systems Market to Reach US$2.4 Billion by 2030

The global market for Label-free Array Systems estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Surface Plasmon Resonance (SPR) Technology, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Bio-layer Interferometry (BLI) Technology segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$484.3 Million While China is Forecast to Grow at 5.3% CAGR

The Label-free Array Systems market in the U.S. is estimated at US$484.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$382.8 Million by the year 2030 trailing a CAGR of 5.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.3% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Label-Free Array Systems Market - Key Trends & Drivers Summarized

How Are Label-Free Array Systems Transforming Biomedical Research?

Label-free array systems have become invaluable tools in biomedical research, offering real-time, non-invasive analysis of biomolecular interactions without the need for fluorescent or radioactive labels. These systems allow scientists to study cell responses, protein interactions, and disease pathways more naturally, making them particularly useful for drug discovery, diagnostics, and biomarker identification. By providing insights into molecular interactions in their native states, label-free technologies support faster, more accurate data collection, enhancing the efficiency of research processes and accelerating the development of new therapeutics.

What Are the Advantages of Label-Free Technology for Drug Discovery?

In drug discovery, label-free array systems enable pharmaceutical researchers to study potential drug interactions directly, minimizing the risk of altering molecular behavior through labeling. This ability to monitor binding affinities, kinetic profiles, and cellular responses in real time improves the accuracy of drug screening processes, making it easier to identify promising compounds in early stages. Additionally, label-free systems reduce costs and time associated with label-based assays, supporting more efficient and cost-effective drug discovery pipelines. This precision and efficiency make label-free array systems a favored approach in modern pharmaceutical research.

How Are Technological Advances Improving Label-Free Systems?

Recent advancements in detection methods, such as surface plasmon resonance (SPR) and bio-layer interferometry (BLI), are enhancing the sensitivity and versatility of label-free array systems. These technologies allow for more refined analysis at smaller scales, making it possible to detect low-abundance biomolecules and analyze complex samples. Automation and integration with data analytics further improve throughput, enabling high-throughput screening for large-scale studies. These improvements in detection and analysis are expanding the applications of label-free systems, increasing their value in research and clinical settings.

The Growth in the Label-Free Array Systems Market Is Driven by Several Factors

The growth in the label-free array systems market is driven by several factors, including the demand for accurate, high-throughput drug discovery tools, advancements in detection technology, and the need for efficient biomolecular analysis. As pharmaceutical and biotech companies seek more precise tools for drug screening, label-free systems offer advantages in speed and accuracy. Technological developments that enhance system sensitivity and allow for real-time monitoring are also expanding market potential. Additionally, the need for effective diagnostic and biomarker discovery tools is bolstering demand for label-free array systems, positioning them as critical instruments in life sciences research.

SCOPE OF STUDY:

The report analyzes the Label-free Array Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Drug Discovery, Antibody Characterization and Development, Protein Interface Analysis, Protein Complex and Cascade Analysis); End-Use (R&D Laboratories, Contract Research Organizations (CROs), Agriculture Research Institutes, Other End-Uses); Technology (Surface Plasmon Resonance (SPR), Bio-layer Interferometry (BLI), Cellular Dielectric Spectroscopy (CDS), Quartz Crystal Microbalance)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â